chronic kidney disease (CKD)
Jump to navigation
Jump to search
Genetics
- FAT10 may mediate NF-kappa-B activation & may promote tubulointerstitial inflammation in chronic kidney diseases
Diagnostic criteria
- abnormal kidney struture or function for > 3 months
- a marker of kidney damage
- albuminuria
- abnormal urine sediment
- electrolyte disorder due to renal tubular dysfunction
- abnormal renal histology
- abnormal renal imaging (structure abnormalities)
- renal transplantation
OR
Laboratory
Radiology
- renal ultrasonography is often the 1st imaging modality[3]
Staging
- GFR or G staging
- albuminuria or A classification
- stage A1: urine albumin/creatinine ratio: < 30 mg/gram
- stage A2: urine albumin/creatinine ratio: 30-300 mg/gram
- stage A3: urine albumin/creatinine ratio: > 300 mg/gram
Complications
Management
Notes
- USPSTF & American College of Physicians recommend against screening asymptomatic adults due to insufficient evidence[2]
- American Society of Nephrology recommends screening all adults[3]
- persons with a family history of chronic kidney disease should be screened[3]
More general terms
More specific terms
- chronic glomerulonephritis
- chronic interstitial nephritis (analgesic nephropathy, drug-induced chronic interstitial nephritis)
- chronic pyelonephritis (xanthogranulomatous pyelonephritis)
- chronic renal failure (CRF)
- genetic disease of the kidney
- polycystic kidney disease
Additional terms
- age-associated changes in renal function
- hospice guidelines for determining prognosis, renal disease
- kidney
References
- ↑ UniProt http://www.uniprot.org/uniprot/O15205.html
- ↑ 2.0 2.1 Moyer VA et al Screening for Chronic Kidney Disease: U.S. Preventive Services Task Force Recommendation Statement Annals of Internal Medicine, Aug 28, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22928171 <Internet> http://annals.org/article.aspx?articleid=1355168 (corresponding NGC guideline withdrawn Feb 2018)
Qaseem A et al Screening, Monitoring, and Treatment of Stage 1 to 3 Chronic Kidney Disease: A Clinical Practice Guideline From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. Published online 22 October 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24145991 <Internet> http://annals.org/article.aspx?articleid=1757302 - ↑ 3.0 3.1 3.2 3.3 3.4 Medical Knowledge Self Assessment Program (MKSAP) 16, 17, 19. American College of Physicians, Philadelphia 2012, 2015, 2021
- ↑ Drawz P, Rahman M. In the clinic. Chronic kidney disease. Ann Intern Med. 2009 Feb 3;150(3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19189903
- ↑ Hage FG, Venkataraman R, Zoghbi GJ et al The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol. 2009 Jun 9;53(23):2129-40. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19497438
- ↑ Navaneethan SD, Pansini F, Perkovic V et al HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009 Apr 15;(2) PMID: https://www.ncbi.nlm.nih.gov/pubmed/19370693
- ↑ Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Mar;5(3):512-8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20133492
- ↑ Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008 Sep;3(5):1563-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18667744
- ↑ Levey AS, de Jong PE, Coresh J et al The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011 Jul;80(1):17-28. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21150873
- ↑ Kalamas AG, Niemann CU. Patients with chronic kidney disease. Med Clin North Am. 2013 Nov;97(6):1109-22. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24182722
- ↑ Yeung WG, Palmer SC, Strippoli GFM et al Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2023 Jun 24:S0272-6386(23)00693-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37356648
- ↑ Owsiany MT, Hawley CE, Triantafylidis LK, Paik JM. Opioid Management in Older Adults with Chronic Kidney Disease: A Review. Am J Med. 2019 Dec;132(12):1386-1393. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31295441 PMCID: PMC6917891 Free PMC article. Review.
- ↑ National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. PMID: https://www.ncbi.nlm.nih.gov/pubmed/11904577
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. KDIGO Kidney International Supplements 2012; 2:288. http://www.kdigo.org/clinical_practice_guidelines/anemia.php